Literature DB >> 28372870

Analysis of outcomes and prognostic factors after fertility-sparing surgery in malignant ovarian germ cell tumors.

Jeong-Yeol Park1, Dae-Yeon Kim2, Dae-Shik Suh2, Jong-Hyeok Kim2, Yong-Man Kim2, Young-Tak Kim2, Joo-Hyun Nam2.   

Abstract

OBJECTIVE: To evaluate the oncologic and reproductive outcomes and to analyze prognostic factors after fertility-sparing surgery in patients with early and advanced malignant ovarian germ cell tumors (MOGCTs).
METHODS: This study included 171 patients who underwent fertility-sparing surgery. Data were gathered from patients' medical records. Survival analysis was performed using the log-rank test and Cox's proportional hazards model. Reproductive outcomes were analyzed.
RESULTS: Twenty-five patients (14.6%) had recurrent disease, and five patients (2.9%) died of disease during the median follow-up time of 86months (range, 9-294months). The 5-year disease-free survival (DFS) was 86%, and the 5-year overall survival (OS) was 97%. The 5-year DFS was 84% for stage I and 89% for stage II-IV. The 5-year OS was 99% for stage I and 91% for stage II-IV. In multivariate analysis, yolk sac tumor, incomplete staging surgery, and residual tumor were independent risk factors for reduced DFS, and yolk sac tumor and residual tumor were independent risk factors for reduced OS. Reproductive and obstetric outcomes were evaluable in 124 patients, and 106 patients (85.5%) had regular menstruation, 12 patients (9.7%) had irregular menstruation, and six patients (4.8%) had premature menopause. Twenty patients tried to conceive, 15 patients (75%) succeeded in achieving 21 pregnancies, and 13 of the patients (65%) gave birth to 20 healthy babies.
CONCLUSION: Fertility-sparing surgery has excellent survival outcomes in young women with MOGCTs, even in advanced stages. Reproductive and obstetric outcomes were promising. Yolk sac tumor, incomplete surgical staging, and residual tumor were independent prognostic factors.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Fertility-sparing surgery; Malignant ovarian germ cell tumor; Oncologic outcome; Ovary; Reproductive outcome

Mesh:

Year:  2017        PMID: 28372870     DOI: 10.1016/j.ygyno.2017.03.023

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  12 in total

1.  The individualized significance of lymphadenectomy across all age groups and histologies in malignant ovarian germ cell tumors.

Authors:  Jieyu Wang; Ruifang Chen; Jun Li; Xin Lu
Journal:  Arch Gynecol Obstet       Date:  2020-09-04       Impact factor: 2.344

2.  Impact of Optimal Therapy and Prognostic Factors in Malignant Germ Cell Tumors of Ovary: 20 Years' Institutional Experience.

Authors:  V R Pallavi; Yamini Kansal; Praveen S Rathod; K Shobha; Rajshekar Kundargi; U D Bafna; Uma Devi; C R Vijay
Journal:  Indian J Surg Oncol       Date:  2022-05-02

3.  Clinical outcome of lymphadenectomy in malignant ovarian germ cell tumors: a systematic review and meta-analysis.

Authors:  Ling Han; Yali Chen; Yana Liu; Ai Zheng; Hengxi Chen
Journal:  Am J Cancer Res       Date:  2022-09-15       Impact factor: 5.942

4.  Depression and anxiety in women with malignant ovarian germ cell (MOGCT) and sex cord stromal tumors (SCST): an analysis of the AGO-CORSETT database.

Authors:  M Bossart; H Plett; B Krämer; E Braicu; B Czogalla; M Klar; S Singer; D Mayr; A Staebler; A du Bois; S Kommoss; T Link; A Burges; F Heitz; M Grube; F Trillsch; P Harter; P Wimberger; P Buderath; A Hasenburg
Journal:  Arch Gynecol Obstet       Date:  2022-09-21       Impact factor: 2.493

5.  Oncological and Reproductive Outcomes in Patients With Advanced-Stage Ovarian Immature Teratoma: Experience From a Tertiary Center.

Authors:  Dan Wang; Wei Cang; Shan Zhu; Congwei Jia; Dongyan Cao; Jiaxin Yang; Yang Xiang
Journal:  Front Oncol       Date:  2022-06-22       Impact factor: 5.738

Review 6.  Non-Epithelial Ovarian Cancers: How Much Do We Really Know?

Authors:  Alison Cheung; Sidrah Shah; Jack Parker; Pavandeep Soor; Anu Limbu; Matin Sheriff; Stergios Boussios
Journal:  Int J Environ Res Public Health       Date:  2022-01-19       Impact factor: 3.390

7.  Fertility-sparing surgery in advanced stage malignant ovarian germ cell tumor: a case report.

Authors:  Montassar Ghalleb; Hatem Bouzaiene; Skander Slim; Achraf Hadiji; Monia Hechiche; Jamel Ben Hassouna; Khaled Rahal
Journal:  J Med Case Rep       Date:  2017-12-17

8.  Fertility sparing surgery in malignant ovarian Germ cell tumor (MOGCT): 15 years experiences.

Authors:  Narges Zamani; Mohadese Rezaei Poor; Sedigheh Ghasemian Dizajmehr; Shima Alizadeh; Mitra Modares Gilani
Journal:  BMC Womens Health       Date:  2021-08-04       Impact factor: 2.809

9.  Germinal ovarian tumors in reproductive age women: Fertility-sparing and outcome.

Authors:  Miriam Dellino; Erica Silvestris; Vera Loizzi; Angelo Paradiso; Rosalia Loiacono; Carla Minoia; Antonella Daniele; Gennaro Cormio
Journal:  Medicine (Baltimore)       Date:  2020-09-25       Impact factor: 1.817

10.  The effect of fertility-sparing surgery on sexuality and global quality of life in women with malignant ovarian germ cell and sex cord stromal tumors: an analysis of the CORSETT database of the AGO study group.

Authors:  Annette Hasenburg; Hellmut Plett; Bernhard Krämer; Elena Braicu; Bastian Czogalla; Michaela Bossart; Susanne Singer; Doris Mayr; Annette Staebler; Andreas du Bois; Stefan Kommoss; Theresa Link; Alexander Burges; Florian Heitz; Jacqueline Keul; Fabian Trillsch; Philipp Harter; Pauline Wimberger; Paul Buderath; Maximilian Klar
Journal:  Arch Gynecol Obstet       Date:  2021-07-21       Impact factor: 2.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.